Marketing-authorisation holder · Ireland
Advanz Pharma Limited
57 medicines in 5 countries, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Ireland
57 medicines in 5 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 57
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AGGRASTATConcentrato per soluzione per infusione | Tirofiban | Italy | Authorised | |
| Aggrastat 0,05 mg/ml oplossing, oplossing voor intraveneuze infusieOplossing voor infusie | Tirofiban | Netherlands | Authorised | 1999 |
| Aggrastat 0,25 mg/ml concentraat, concentraat voor oplossing voor intraveneuze infusieConcentraat voor oplossing voor infusie | Tirofiban | Netherlands | Authorised | 1999 |
| AGRASTAT 0,05 mg/ml SOLUCION PARA PERFUSION56,18 µg · Solución para perfusión | Tirofiban | Spain | Marketed | 1999 |
| AGRASTAT 0,25 mg/ml CONCENTRADO PARA SOLUCIÓN PARA PERFUSION0,281 mg · Concentrado para solución para perfusión | Tirofiban | Spain | Marketed | 1999 |
| ANDROCURCompressa | Cyproterone | Italy | Authorised | |
| Androcur 10, tabletten 10 mgTablet | Cyproterone | Netherlands | Authorised | 1981 |
| ANDROCUR 50 mg COMPRIMIDOS50 mg · Comprimido | Cyproterone | Spain | Marketed | 1974 |
| Androcur 50 mg tabletetableta | Cyproterone | Croatia | Marketed | 2025 |
| Androcur 50, tabletten 50 mgTablet | Cyproterone | Netherlands | Authorised | 1973 |
| Androcur Depot, oplossing voor injectie 300 mg/3 mlOplossing voor injectie | Cyproterone | Netherlands | Authorised | 1980 |
| Brinavess | Vernakalant | EU (EMA) | Authorised | 2010 |
| BRINAVESSConcentrato per soluzione per infusione | Vernakalant | Italy | Authorised | |
| Brinavess 20 mg / ml, concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Vernakalant | Netherlands | Authorised | 2010 |
| BRINAVESS 20 mg/ml, CONCENTRADO PARA SOLUCION PARA PERFUSION20 mg · Concentrado para solución para perfusión | Vernakalant | Spain | Marketed | 2010 |
| DALBAVANCINA ADVANZ PHARMA 500 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION EFG516 mg · Polvo para concentrado para solución para perfusión | Dalbavancin | Spain | Marketed | 2025 |
| ERIBULINA ADVANZ PHARMASoluzione iniettabile | Eribulin | Italy | Authorised | |
| ERIBULINA ADVANZ PHARMA 0,44 MG/ML SOLUCIÓN INYECTABLE EFG0,5 mg/ml · Solución inyectable | Eribulin | Spain | Marketed | 2023 |
| EXBLIFEPPolvere per concentrato per soluzione per infusione | Cefepime, Enmetazobactam | Italy | Authorised | |
| Exblifep | Cefepime, Enmetazobactam | EU (EMA) | Authorised | 2024 |
| EXBLIFEP 2 g/0,5 g, poeder voor concentraat voor oplossing voor infusiePoeder voor concentraat voor oplossing voor infusie | Cefepime, Enmetazobactam | Netherlands | Authorised | 2024 |
| EXBLIFEP 2 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION2378 mg + 500 mg · Polvo para concentrado para solución para perfusión | Cefepima dihidrocloruro, Enmetazobactam | Spain | Marketed | 2024 |
| Gobivaz | Golimumab | EU (EMA) | Authorised | 2025 |
| GOBIVAZSoluzione iniettabile in penna pre-riempita | Golimumab | Italy | Authorised | |
| GOBIVAZ 100 mg oplossing voor injectie in een voorgevulde penOplossing voor injectie | Golimumab | Netherlands | Authorised | 2025 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Netherlands | 20 | 20 | 0 | CompaniesAll medicines |
| Spain | 17 | 15 | 2 | CompaniesAll medicines |
| Italy | 12 | 12 | 0 | CompaniesAll medicines |
| European Union (EMA) | 7 | 4 | 3 | CompaniesAll medicines |
| Croatia | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of France
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Contains Irish Public Sector Data licensed under Creative Commons Attribution 4.0 International (CC BY 4.0), Companies Registration Office; original dataset/API URL and company number, exact locator/source version and retrieval date; selected field normalization by Prognia. https://creativecommons.org/licenses/by/4.0/
Licence: Creative Commons Attribution
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.